Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001576885-24-000098
Filing Date
2024-11-12
Accepted
2024-11-12 16:29:19
Documents
69
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q abos-20240930.htm   iXBRL 10-Q 922141
2 EX-31.1 abos-20240930x10qxexx311.htm EX-31.1 10686
3 EX-31.2 abos-20240930x10qxexx312.htm EX-31.2 10649
4 EX-32.1 abos-20240930x10qxexx321.htm EX-32.1 5028
5 EX-32.2 abos-20240930x10qxexx322.htm EX-32.2 5071
  Complete submission text file 0001576885-24-000098.txt   5957991

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abos-20240930.xsd EX-101.SCH 43200
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT abos-20240930_cal.xml EX-101.CAL 77917
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT abos-20240930_def.xml EX-101.DEF 212279
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT abos-20240930_lab.xml EX-101.LAB 623910
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT abos-20240930_pre.xml EX-101.PRE 421247
72 EXTRACTED XBRL INSTANCE DOCUMENT abos-20240930_htm.xml XML 757496
Mailing Address 427 PARK ST. CHARLOTTESVILLE VA 22902
Business Address 427 PARK ST. CHARLOTTESVILLE VA 22902 925-368-8508
Acumen Pharmaceuticals, Inc. (Filer) CIK: 0001576885 (see all company filings)

EIN.: 364108129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40551 | Film No.: 241448785
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)